Status:
COMPLETED
Sunphenon in Progressive Forms of Multiple Sclerosis
Lead Sponsor:
Friedemann Paul
Collaborating Sponsors:
TAIYO EUROPE
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
The investigators hypothesize that an oral Sunphenon EGCg (Epigallocatechin-Gallat, EGCG) treatment is - due to its antiinflamatoric and neuroprotective potence - significantly more effective than an ...
Detailed Description
The hypotheses of our study are: Sunphenon EGCg has an antiinflammatoric effect due to its impact on the T-cell-proliferation and the inhibition of the activity of NF-Kb. Sunphenon EGCg has a neurop...
Eligibility Criteria
Inclusion
- Primary or secondary chronic progressive multiple sclerosis (ms)
- EDSS 3-8
- Age 18-65
Exclusion
- Relapsing-remitting ms
- Immunodulatoric or immunosuppressive therapy
- pretreatment with Mitoxantron, Natalizumab, Rituximab, Azathioprin \<2 month before screening
- pretreatment with Glairameracetat or beta-Interferons \<4 weeks before screening
- signs of hepatic dysfunction
- active ulcus ventriculi or duodeni
- neoplasias if not cured \>1 year before screening
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00799890
Start Date
May 1 2009
End Date
March 1 2016
Last Update
July 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätsmedizin Berlin (NeuroCure Clinical Research Center)
Berlin, Germany, 10117